Vita Genomics, Inc.

Authors: Shih-Hsin Wu, Lawrence; Su, Chun-lin; Chen, Ellson

Source: Pharmacogenomics, Volume 8, Number 6, June 2007 , pp. 669-673(5)

Buy & download fulltext article:

Price: $63.00 plus tax (Refund Policy)

Abstract:

Vita Genomics, Inc., centered in Taiwan and China, aims to be a premier genomics-based biotechnological and biopharmaceutical company in the Asia--Pacific region. The company focuses on conducting pharmacogenomics research, in vitro diagnosis product development and specialty contract research services in both genomics and pharmacogenomics fields. We are now initiating a drug rescue program designed to resurrect drugs that have failed in the previous clinical trials owing to low efficacies. This program applies pharmacogenomics approaches using biomarkers to screen subsets of patients who may respond better or avoid adverse responses to the test drugs. Vita Genomics, Inc. has envisioned itself as an important player in the healthcare industry offering advanced molecular diagnostic products and services, revolutionizing thedrug-development process and providing pharmacogenomic solutions.

Keywords: contract research organizations; personalized medicine; pharmacogenomics; SNP

Document Type: Research article

DOI: http://dx.doi.org/10.2217/14622416.8.6.669

Affiliations: 1: 1Vita Genomics, Inc., 7Fl. No.6, Sec.1, Jungshing Rd., Wugu Shiang, Taipei, 248 Taiwan., Email: ellson.chen@vitagenomics.com

Publication date: 2007-06-01

More about this publication?

Pharmacogenomics provides the community with an essential resource for keeping abreast of the latest developments in new pharmacogenomic initiatives, emerging technologies for accessing genomic information and the development of novel diagnostic products and strategies.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
E-Access Trials
ingentaconnect is not responsible for the content or availability of external websites